Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **ceramide biosynthesis pathway** refers to a series of interconnected metabolic routes responsible for the generation and regulation of **ceramides**, which are central sphingolipid molecules involved in both structural and signaling roles within eukaryotic cells. There are three main pathways for ceramide generation: 1. **De novo synthesis** begins with the condensation of serine and palmitoyl-CoA catalyzed by serine palmitoyltransferase—this is the rate-limiting step—and proceeds through several enzymatic steps in the endoplasmic reticulum to produce dihydroceramide, which is then desaturated into ceramide by dihydroceramide desaturase[1][6][9]. 2. The **sphingomyelinase pathway** involves hydrolysis of sphingomyelin in cellular membranes by sphingomyelinases (acidic/neutral), releasing free ceramides; this process is often activated during stress responses such as apoptosis induced by radiation or cytokines[1][3]. 3. The **salvage/recycling pathways** convert complex sphingolipids back into sphingosine and then reacylate it via various synthases to regenerate ceramides; this allows dynamic regulation based on cellular needs and stressors[1][3]. Ceramides produced through these pathways act as bioactive lipids that regulate diverse processes including programmed cell death (apoptosis), autophagy, cell proliferation/differentiation, myelination in neurons, mitochondrial function, and response to cellular stressors like inflammation or oxidative damage. Dysregulation contributes significantly to pathologies such as cancer progression (where they may act as tumor suppressor lipids), neurodegeneration (notably demyelinating diseases like multiple sclerosis), cardiovascular dysfunctions, diabetes/metabolic syndrome, among others[2][3][7]. While individual enzymes within this network—such as serine palmitoyltransferase or specific isoforms of ceramide synthases—are considered therapeutic targets due to their druggability and disease relevance,[4] the "ceramide biosynthesis pathway" itself is not a single molecular target but rather a collection of enzymatic activities forming a metabolic network. Therefore, > "Ceramide biosynthesis pathway" does not refer to one discrete molecule/receptor but rather an ensemble process involving multiple enzyme targets. This makes it an incorrect entry if you are seeking information about a single canonical molecular target suitable for structured drug-target databases. References used above provide detailed mechanistic insights into each step/enzyme involved in these processes.[1][2][3]
Inhibition of key enzymes such as serine palmitoyltransferase or ceramide synthases to reduce ceramide production[5][8]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ceramide biosynthesis pathway.